TRAVERE THERAPEUTICS, INC. Co Selected Measure Amt
TRAVERE THERAPEUTICS, INC. (TVTX) reported Co Selected Measure Amt of $410.46 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-06.
Financial Statements › Notes
ecd:CoSelectedMeasureAmt · last filed 2026-04-06
| Period end | Co Selected Measure Amt 12 month |
|---|---|
| 2025-12-31 | $410.46M DEF 14A · filed 2026-04-06 |
| 2024-12-31 | $226.71M DEF 14A · filed 2026-04-06 |
| 2023-12-31 | $127.54M DEF 14A · filed 2026-04-06 |
| 2022-12-31 | $200.53M DEF 14A · filed 2026-04-06 |
| 2021-12-31 | $210.78M DEF 14A · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |